Market Newsdesk

SUNNYVALE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) —

John Maddison, EVP of Products and CMO at Fortinet

“Organizations are increasingly seeking technology that converges network infrastructure with security to simplify operations and break down siloes. This convergence, Security-Driven Networking, is the vision Fortinet was founded on 20 years ago and is showcased in our industry-leading Secure SD-WAN solution. Fortinet’s unique approach to SD-WAN enables service providers to be flexible and agile to quickly deliver differentiated value-added services that effectively address customer challenges while significantly reducing costs.”

News Summary

Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated and automated cybersecurity solutions, today announced new service providers from around the globe have selected Fortinet Secure SD-WAN to deliver new value-added services. These six organizations, including Fireminds, Netpluz, NG-BLU Networks, MTN Business Kenya, TPx and Vox Telecom, join a large number of existing SPs and MSSPs that are expanding their customer offerings powered by Secure SD-WAN.

Fortinet Secure SD-WAN
: A
Leading Solution for Service Providers

As organizations build more robust WAN infrastructures, managing and troubleshooting complex network issues require a significant amount of time and is usually very costly. Service providers are helping customers overcome these challenges by building new services that leverage Fortinet’s unified Secure SD-WAN solution. Fortinet Secure SD-WAN converges advanced networking and security to reduce point products and complexity at the WAN edge, providing the industry’s best total cost of ownership. Service providers are selecting Fortinet Secure SD-WAN as the foundation of their offerings for the following reasons:

• Most Comprehensive SD-WAN Solution: Fortinet Secure SD-WAN offers an all-in-one solution, combining advanced routing, integrated next-generation firewall (NGFW), self-healing SD-WAN capabilities and intuitive orchestration. SPs using Fortinet Secure SD-WAN are helping their customers achieve the best possible user experience while making it significantly easier for teams to manage deployments and reduce operational costs.
• Gartner Magic Quadrant Leader: Fortinet is a Leader in the 2020 Gartner Magic Quadrant for WAN Edge Infrastructure and Magic Quadrant for Network Firewalls reports. Fortinet is evaluated based on their completeness of vision and ability to execute both for the same FortiGate platform.
• Enable
  Differentiated Services
  for WAN Edge Transf
  o
  rmation
  Across all Edges: With Fortinet Secure SD-WAN’s extensive solution available via appliance, VM and for all major public cloud providers, SPs are able to offer SD-WAN services that can be deployed anywhere across the home, branch, campus or multiple clouds. With Fortinet’s integrated solution, SPs can go beyond simply delivering connectivity services thereby expanding their offerings to include hybrid WAN and SD-Branch access services, as well as ensure cloud edge access for multi-cloud environments and the cloud on-ramp. As a result, SPs who choose Fortinet are able to help their customers address the broadest set of deployments while achieving reliable and secure access anytime and anywhere.

Service Providers
Expand Offerings Powered by Fortinet

Here’s what SPs from around the world have to say about Fortinet Secure SD-WAN’s impact on their business growth and expansion.

“As a cloud and managed service provider, Fireminds is constantly looking to improve our customers’ and partners’ network resilience and security. The integration of security and SD-WAN that Fortinet has enabled has been a key driver in our ability to serve our customers across the Caribbean and the USA. Incorporating Fortinet into both our regional network and our customer product catalogue has been key to delivering a high-quality user experience, resulting in increased business productivity, agility and reduced costs for our customers and partners.”
– Conor McGowan, Sales Vice President at Fireminds

“As a Fortinet-powered managed security service provider, MTN Business Kenya is delivering security and SD-WAN solutions that give our customers an agile network and the ability to securely incorporate the latest digital innovations. Most of our corporate clients operate in a fast-paced environment that constantly faces attempts of cyber-attacks. In addition, most clients are challenged by heavy CAPEX on security appliances and high costs of maintaining highly-skilled cybersecurity professionals. To help organizations address such challenges, MTN Business Kenya partnered with Fortinet to deliver security as a service. As a result, we have seen tremendous growth in service uptake and peace of mind for our customers. Our clients value the advanced security protection, pay-as-you-go model and faster deployments that Fortinet enables us to provide.”
– Tseleng Thathane- Ag., Managing Director at MTN Business Kenya

“With the evolving technology landscape and pressure on delivering guaranteed user experience, organizations realize that the need to prioritize security and network performance to deliver high availability for business applications is critical. The need for high availability and the arduous demand on traditional WAN infrastructure has become harder to manage and scale, commercially and securely. Leveraging the Fortinet Secure SD-WAN technology differentiates our managed connectivity service offerings to our customers and enables them to connect with confidence. With advance security, flexibility and lower TCO, we noticed instant resource savings based on simpler administration tasks and better workload performance and security.”
– Lau Leng Fong, Chief Executive Officer at Netpluz Asia

“Fortinet’s product portfolio has always been key to our Cloud security solutions. We’ve expanded our partnership by creating a complete SD-WAN portfolio powered by Fortinet. We’ve been able to improve the internet performance and connectivity availability for our customers, while also realizing a substantial decrease of TCO. Our SD-WAN portfolio has been developed for both multi-site and single-site customers. Fortinet empowers us to effectively address the entire business-to-business market, leading to an enormous potential for our ICT partners.”
-Jacco Kouwenberg, CCO at NG-BLU Networks

“By combining market-leading security with SD-WAN, VPN, dynamic routing and comprehensive reporting in a single solution, Fortinet Secure SD-WAN is key to enabling TPx to bring enterprise-grade networking and cybersecurity services to our small and medium business (SMB) customers at a price they can afford. Our network and security professionals deploy, manage and monitor the TPx Secure SD-WAN service, which gives customers visibility and control of their network, helps them meet compliance requirements, reduce exposure to cyberattacks and minimize downtime.”
– Jared Martin, Vice President of MSx Managed Services at TPx

“We are thrilled to continue extending our Platinum partner status with Fortinet, being a worldwide leader in security and SD-WAN. Fortinet is an ideal partner that aligns with the Vox business strategy and culture. Vox has an established customer base with Fortinet and this strategic partnership will allow us to add continuous value to our customers, ensuring that security remains a high priority across Vox SD-WAN services. More than ever, companies have a greater need for security, especially given the rise in web and security threats post-COVID.”
– Mike Kuczmierczyk, Senior Product Manager SD-WAN at Vox

Additional Resources

• Access a complimentary copy of the 2020 Gartner Magic Quadrant for WAN Edge Infrastructure.
• Access the November 2020 Gartner Magic Quadrant for Network Firewalls.
• Find out how the Fortinet Security Fabric platform delivers broad, integrated, and automated protection across an organization’s entire digital infrastructure.
• Read about other service providers leveraging Secure SD-WAN here and here.
• Learn more about FortiGuard Labs threat intelligence and research and the FortiGuard Security Subscriptions and Services portfolio.
• Read more about how Fortinet customers are securing their organizations.
• Learn more about Fortinet’s Network Security Expert (NSE) Training Institute, including its free cybersecurity training initiative, the NSE Certification Program, Security Academy Program and Veterans Program.
• Engage in the Fortinet User Community (Fuse). Share ideas and feedback, learn more about our products and technology, and connect with peers.
• Follow Fortinet on Twitter, LinkedIn, Facebook, YouTube, and Instagram. 

About Fortinet

Fortinet (NASDAQ: FTNT) secures the largest enterprise, service provider, and government organizations around the world. Fortinet empowers our customers with complete visibility and control across the expanding attack surface and the power to take on ever-increasing performance requirements today and into the future. Only the Fortinet Security Fabric platform can address the most critical security challenges and protect data across the entire digital infrastructure, whether in networked, application, multi-cloud or edge environments. Fortinet ranks #1 in the most security appliances shipped worldwide and more than 465,000 customers trust Fortinet to protect their businesses. Both a technology company and a learning organization, the Fortinet Network Security Expert (NSE) Training Institute has one of the largest and broadest cybersecurity training programs in the industry. Learn more at http://www.fortinet.com, the Fortinet Blog, or FortiGuard Labs.

FTNT-O

Copyright © 2020 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiCore, FortiMail, FortiSandbox, FortiADC, FortiAI, FortiAP, FortiAppEngine, FortiAppMonitor, FortiAuthenticator, FortiBalancer, FortiBIOS, FortiBridge, FortiCache, FortiCam, FortiCamera, FortiCarrier, FortiCASB, FortiCenter, FortiCentral,FortiConnect, FortiController, FortiConverter, FortiCWP, FortiDB, FortiDDoS, FortiDeceptor, FortiDirector, FortiDNS, FortiEDR, FortiExplorer, FortiExtender, FortiFone, FortiHypervisor, FortiInsight, FortiIsolator, FortiLocator, FortiLog, FortiMeter, FortiMoM, FortiMonitor, FortiNAC, FortiPartner, FortiPortal, FortiPresence , FortiProtect, FortiProxy, FortiRecorder, FortiReporter, FortiScan, FortiSDNConnector, FortiSIEM, FortiSDWAN, FortiSMS, FortiSOAR, FortiSwitch, FortiTester, FortiToken, FortiTrust, FortiVoice, FortiVoIP, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLCOS and FortiWLM.

Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments. This news release may contain forward-looking statements that involve uncertainties and assumptions, such as statements regarding technology releases among others. Changes of circumstances, product release delays, or other risks as stated in our filings with the Securities and Exchange Commission, located at www.sec.gov, may cause results to differ materially from those expressed or implied in this press release. If the uncertainties materialize or the assumptions prove incorrect, results may differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Fortinet assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to update these forward-looking statements.

Media Contact:	Investor Contact:	Analyst Contact:
Stephanie Lira	Peter Salkowski	Ron Davis
Fortinet, Inc.	Fortinet, Inc.	Fortinet, Inc.
408-235-7700	408-331-4595	415-806-9892
[email protected]	[email protected]	[email protected]

STMicroelectronics Announces Mass-Market Availability
of STM32WL LoRa^®-Compatible Wireless System-on-Chip Family

• Market-unique LoRa-compatible multi-modulation SoC drives innovation in IoT connectivity
• Mass-market introduction extends feature options, packages, and protocols compatibility (e.g. Sigfox)
• Dual-core variant boosts performance, cyber-security, and flexibility

Geneva, December 9, 2020 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, has expanded availability of its market-unique STM32WL long-range sub-GHz wireless system-on-chip (SoC) family, adding flexible configurations and package options for diverse mass-market applications.

As the only SoC ICs featured to connect devices to LoRa-based Low-Power Wide-Area Networks (LPWANs), the STM32WL series lets users create Internet-of-Things (IoT) devices that are extremely compact, energy efficient, and reliable. LPWANs provide cost-effective connectivity over large geographical areas and in remote locations, extending the IoT’s reach and enabling smart technologies to add greater value in industries from utilities and agriculture to shipping, transportation, and others.

“Long-range IoT networks like LoRaWAN or Sigfox now cover the globe, ready to connect innovative and highly useful smart devices in applications such as environmental monitoring and asset tracking,” said Ricardo de Sa Earp, Group Vice President, Microcontroller Division General Manager, STMicroelectronics. “Mass-market access to our unique single-chip integrated microcontroller and multi-modulation radio will broaden development of exciting new products that leverage these networks and deliver unparalleled functionality, usability, and value.”

The STM32WL series combines ST’s STM32 ultra-low-power microcontroller (MCU) architecture with a sub-GHz radio subsystem that supports multiple modulation schemes. These include both LoRa, which allows high receiving sensitivity at low RF signal power, and (G)FSK, (G)MSK and BPSK modulation used by Sigfox and wireless Meter-Bus (wM-Bus) protocols for instance as well as other proprietary protocols or sub-GHz standards. The radio has a selectable dual-power output that helps customers comply with RF-power restrictions for unlicensed frequency bands in all territories worldwide.

The new STM32WL models introduced today include the dual-core STM32WL55, based on an Arm^® Cortex^®-M4 core and a Cortex-M0+ MCU core which can both be used in a fully open and flexible way. The dual-core architecture effectively ensures hardware isolation that enhances cybersecurity, allows application updates without the need to re-certify the device as a new radio product, and enhances real-time performance of both the radio and application.
The STM32WL55 joins the single-core STM32WLE5 introduced in January 2020 in BGA73 and QFN48 packages, which uses the main Cortex-M4 core to handle the radio and the application. The extended lineup also adds two non-LoRa variants, the single-core STM32WLE4 and dual-core STM32WL54, allowing developers flexibility to leverage the unique SoC in new wireless IoT projects. All devices are supported by ST’s rolling 10-year longevity commitment for industrial products.

Please contact your ST sales office for pricing options and sample requests.

Please visit www.st.com/stm32wl for more information.

Further technical information:

Monolithic integration of ST’s STM32 ultra-low-power architecture and sub-GHz multi-modulation radio featuring LoRa modulation makes the STM32WL series unique in the market.
The radio is based on proven Semtech SX126x transceiver IP, specially re-engineered by ST to fit market-proven power modes of STM32 platforms. It contains two internal power amplifiers with 15dBm and 22dBm maximum transmit power: The high-power and low-power transmitter modes, covering the global unlicensed frequency range from 150MHz to 960MHz, ensure compatibility with Low-Power Wide Area Networks in all territories and allow STM32WL SoCs to power end-products that are marketed worldwide.

The high level of RF integration, enables single-crystal synchronization of the High-Speed External (HSE) clock and radio, and with no need for an external power amplifier (PA), which serves to minimize the overall Bill of Materials (BoM) cost and solution footprint. ST’s STM32WL architecture, leveraging the energy-efficient and powerful Arm Cortex-M4 core with DSP extensions, benefits from ultra-low-power technologies including dynamic voltage scaling and ST’s adaptive real-time ART Accelerator™ for zero-wait execution from Flash. MCU Flash options up to 256Kbyte let developers choose the optimal code and data storage density for the entire platform including application and radio.

Built-in cyber-security features include hardware symmetric encryption and Public Key Accelerators, True Random Number Generator (TRNG), sector protection against read/write operation, dual-core secure areas isolation and support for state-of-the-art cryptographic algorithms including RSA, ECC and ECDSA.

Moreover, users can take advantage of the proven STM32Cube development ecosystem to simplify product creation and accelerate time to market. Such free resources include the STM32CubeMX project configuration and code generation tool, STM32CubeMonitor runtime monitoring and visualization tool, and STM32CubeProgrammer.

The STM32CubeWL MCU package contains all the embedded software bricks needed to operate the STM32WL series, including peripheral drivers, ST’s LoRaWAN protocol stack, Sigfox stack, and example code for LoRaWAN Firmware Update Over The Air (FUOTA) leveraging ST’s Secure Boot and Secure Firmware Update (SBSFU) technology. Alternative stacks by Authorized Partners, such as the Stackforce W-MBus stack, are also available.
There are also two STM32WL-based Nucleo boards for fast prototyping: NUCLEO-WL55JC1 (868/915/923 MHz) and NUCLEO-WL55JC2 (433/470 MHz).

STM32 is a registered and/or unregistered trademark of STMicroelectronics International NV or its affiliates in the EU and/or elsewhere. In particular, STM32 is registered in the US Patent and Trademark Office.

About STMicroelectronics

At ST, we are 46,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An independent device manufacturer, we work with our 100,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of the Internet of Things and 5G technology. Further information can be found at www.st.com.

For Press Information Contact:

Michael Markowitz
Director Technical Media Relations
STMicroelectronics
Tel: +1 781 591 0354
Email: [email protected]

Attachments

• P4314S — Dec 9 2020 — STM32WL MM launch_FINAL FOR PUBLICATION
• P4314S — Dec 9 2020 — STM32WL MM launch_IMAGE

• AI-based predictive models can optimize the planning of smarter cities and more efficient road networks
• Results to be presented at the Conference on Neural Information Processing Systems (NeurIPS), the leading global machine learning event

NeurIPS, Vancouver – The Institute for Advanced Research in Artificial Intelligence (IARAI), an independent global machine learning research institute established by HERE Technologies, today announced the results and winners of the second edition of its Traffic4cast competition. The goal of the competition is to predict traffic in multiple, global, major cities with varying cultural and economic backdrops, based on industrial-scale traffic data provided by HERE.

Traffic congestion is an issue for cities worldwide and it comes with a negative social and environmental impact. Making mobility more sustainable remains one of the biggest challenges of our times. The Traffic4cast competition series aims to get to the core of this issue by challenging participants to understand complex traffic systems, with the goal of predicting their future states. Advanced traffic prediction is enabled by capturing simple, implicit rules underlying a complex system and modeling its behavior. As a result, superior AI-based predictive models can optimize the planning of smarter cities and more efficient road networks.

“Our design for this year’s competition was heavily influenced by what we learnt from Traffic4cast 2019. This year, we provided more granular data and doubled down on the question of whether ancillary static and dynamic data, like the number of restaurants in each cell and the number road incidents we observed, would improve the results or give rise to other creative winning architectures. The results surprised us on both fronts,” said Michael Kopp, Head of Research at HERE and founding co-director of IARAI. “Through our bonus challenge we also saw approaches that can translate between the dynamics we observe in traffic and ancillary dynamics dependent on it. As a result, questions of how weather and traffic movements are related or whether we can predict the movement of different classes of road vehicles, such as two-wheelers by observing mostly four-wheelers, through this gridded spatio-temporal aggregation approach can now be tackled.”

The winning teams hailing from South Korea, China, Sweden and the US were among more than 26 teams from around the world which submitted over 54 entries.

1st prize: Sungbin Choi
The top-ranking solution achieved the best performance by averaging several models based on UNet, a convolutional neural network (CNN) used for image segmentation. The models contain encoder and decoder blocks with skip connections and varying combinations of densely connected convolutional layers and pooling layers, with different connections between them.

2nd prize: TLabV2 team
TLabV2 team implemented spatio-temporal predictions to the High-Resolution Network (HRNet) architecture that maintains high-resolution representations in image segmentation. The authors introduced a new method of geo-embedding in order to learn the inherent attributes of each geographic location and introduced additional time, weekday, and holiday features as channels to improve the model performance.

3rd prize: LDS group
LDS group implemented a CNN based on UNet architecture, containing dense blocks of convolutional layers, pooling layers, and transpose convolutional layers. The model incorporates city road networks as strong prior knowledge by generating roadmap mask frames for each city based on the average traffic speed and applying them to the output.

As in 2019, the results of theTraffic4cast competition will again be presented at the prestigious Conference on Neural Information Processing Systems (NeurIPS) during a special session on Dec 11.

IARAI is both a Platinum Sponsor and the Traffic4cast Competition organizer at NeurIPS 2020. The institute is hosting several high-profile events, including two fireside chats:
Hopfield Networks in 2021 – fireside chat between Sepp Hochreiter and Dmitry Krotov on Wednesday, December 9 at 7:00 PM – 8:00 PM CET (10:00 AM – 11:00 AM PST) and Performers and Memory – fireside chat between Sepp Hochreiter, Krzysztof Choromanski and Johannes Brandstetter on Thursday, December 10 at 7:00 PM – 9:00 PM CET (10:00 AM – 12:00 PM PST)

Please see here the full agenda of events: https://www.iarai.ac.at/news/iarai-events-at-the-neurips-2020-conference/

Media Contact
Dr. Sebastian Kurme
+49 173 5153549
[email protected]

About HERE Technologies
HERE, a location data and technology platform, moves people, businesses and cities forward by harnessing the power of location. By leveraging our open platform, we empower our customers to achieve better outcomes – from helping a city manage its infrastructure or a business optimize its assets to guiding drivers to their destination safely. To learn more about HERE, please visit www.here.com and http://360.here.com

CHICAGO, Dec. 09, 2020 (GLOBE NEWSWIRE) — Highly regulated companies can no longer focus solely on complying with environmental regulations. Investors, organizational leadership and the public expect maximum asset performance along with a reduced environmental impact. To help companies meet these expectations, Sphera, a leading global provider of Integrated Risk Management software, data and consulting services, has released a new cloud-based Environmental Accounting solution that reduces users’ regulatory compliance burden while delivering advanced insights to improve environmental sustainability.

The new Environmental Accounting solution is available on SpheraCloud, Sphera’s multitenant, Software as a Service (SaaS) and mobile platform that provides an integrated suite of applications to proactively mitigate and manage safety, sustainability and productivity risks across an enterprise.

SpheraCloud Environmental Accounting offers a broad set of data management and calculation functionality for emissions inventory, corporate reporting and greenhouse gas reporting required to support today’s rigorous regulatory programs.

Without the right technology and tools in place, managing the complexity of required regulatory reporting leaves little time to focus on optimization. SpheraCloud Environmental Accounting presents both quantitative and qualitative data about emissions management in a single, dynamic screen. It dramatically reduces the time and effort to create reports and informational views, which saves time and allows for the proactive mitigation of risks from noncompliance.

SpheraCloud Environmental Accounting brings high transparency to a company’s emissions calculation. The data also powers corporate sustainability initiatives by feeding accurate, centralized and standardized emissions data into corporate reporting tools and helps ensure compliance with a single, traceable corporate system of record for emissions and operations data.

“Building on Sphera’s decades of experience using the powerful and trusted emissions calculation engine, we have now made the architecture and platform a fully integrated risk management offering for SpheraCloud,” said Sphera President and CEO Paul Marushka. “We have further enhanced all facets of the user experience to make everything—from data entry to troubleshooting to reporting—seamless. It is all powered by the real-time calculation engine that provides immediate actionable insights to drive performance. Additionally, SpheraCloud Environmental Accounting is designed to have customers up and running quickly for a faster return on investment.”

Watch the demo video or view the brochure to learn how Sphera’s Environmental Accounting solutions can help move your organization from environmental compliance to environmental performance.

About Sphera

Sphera creates a safer, more sustainable and productive world. Our innovative cloud-based risk management platform connects an unprecedented amount of information that leads to deeper insights across an enterprise. We operationalize, scale and optimize Integrated Risk Management strategies to help customers identify, manage and mitigate risk in the areas of Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship.

For further information
or to request an interview
, please contact:

Ellen Bremseth, Manager, Marketing Comms, Sphera, [email protected]

TAMPA, Fla., Dec. 09, 2020 (GLOBE NEWSWIRE) — IVANS®, a division of Applied Systems®, today announced the November results of the IVANS Index™, the insurance industry’s premium renewal rate index. Year over year, all lines of business experienced an increase in average premium renewal rate, except Workers’ Compensation, which saw a negative change in premium. Premium renewal rates, month over month, across major commercial lines of business experienced variability, with an increase for Business Owners Policy,  BOP, General Liability, Commercial Property and Workers’ Compensation and a decrease for Commercial Auto and Umbrella.

Premium renewal rate change by line of business for November 2020 highlights include:

• Commercial Auto: 3.93%, down from 4.43% last month.
• BOP: 4.68%, up from 4.39% at the end of October.
• General Liability: 3.43%, up from 3.38% the month prior.
• Commercial Property: 5.66%, up from 5.52% in October.
• Umbrella: 2.82%, down from 3.78% the month prior.
• Workers’ Compensation: -1.90%, up from -2.78% last month.

 

“The IVANS Index continues to show hardening rates across major lines of business, but with slight softening of rates relative to months prior for Commercial Auto and Umbrella,” said Kathy Hrach, vice president of Product Management, IVANS Insurance Services. “As the economy continues to respond to the effects of the pandemic, the IVANS Index will deliver data-driven insights for agents’ renewal discussions and for insurers as they make 2021 pricing decisions.”

Released on a monthly basis, IVANS Index is a data-driven report of current conditions and trends for premium rate renewal change of the most placed commercial lines of business in the insurance industry. Analyzing more than 120 million data transactions, the IVANS Index premium renewal rate change measures the premium difference year over year for a single consistent policy. Inclusive of more than 32,000 agencies and 400 insurers and MGAs, the IVANS Index is reflective of the premium rate change trends being experienced by all agencies and insurers across the U.S. insurance market. IVANS Index is available to agencies and insurers as part of Market Insights at markets.ivansinsurance.com.

Download the complete Q3 IVANS Index report here.

The IVANS logos are trademarks of Applied Systems, Inc., registered in the U.S.

About IVANS

IVANS, a division of Applied Systems, is the insurance industry’s exchange connecting insurers, MGAs, agencies, and the insured. IVANS cloud-based software automates the distribution and servicing of insurance products. IVANS innovation and expertise connects 32,000 independent insurance agencies and 400 MGA and insurer partners to enable millions of people to safeguard and protect what matters most in people’s lives.

Lauren Malcolm
Applied Systems
[email protected]

SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) — SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020.

This study highlighted the utility of the PARIS® Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in heterogeneous disease such as breast cancer. Authors found that the PARIS® Test:

• Showed a high success rate (70.5%) in delivering a report ranking targeted, endocrine and chemotherapy agents in a clinically relevant timeframe for a cohort of metastatic, heavily pre-treated breast cancer patients.
• Showed high genomic concordance between known actionable biomarkers, such as PIK3CA and FGFR1/FGFR2, and PARIS® Test organoid drug sensitivity.
• Identified candidate therapies in most patients lacking known druggable biomarkers.
• Guided oncologist treatment decisions in 50% of post-assay interventions.

“At SEngine, our main commitment is to improve outcomes for people with cancer,” stated Astrid Margossian, MD, PhD, Chief Medical Officer of SEngine Precision Medicine and lead author. “This commitment is exemplified by this exciting data utilizing our PARIS® Test across the breast cancer spectrum that showed a very strong predictive value between PARIS® Test drug responses and clinical benefit. The actionable report generated by the PARIS® Test influenced physicians and guided treatment decisions in 50% of cases.”

VK Gadi, MD, PhD, co-founder and Medical Advisor of SEngine Precision Medicine, added, “Management of advanced breast cancer has moved steadily away from rigid, canonical and stepwise care towards context-specific and personalized strategies that integrate clinical, pathologic, and genomic data. PARIS® adds the next dimension with functional responses to drugs and combinations to make the very best and most precise therapeutic choices for our patients.”

Carla Grandori, MD, PhD, co-founder and CEO of SEngine Precision Medicine, noted, “Functional testing is a new tool enabling oncologists to select treatments for patients where both the standard of care and current precision medicine approaches, such as DNA sequencing, fail. Oncologists at leading cancer centers across the United States and around the globe are adopting the functional PARIS® Test to bring personalized and precise treatments to patients with the greatest unmet medical need across all solid tumor types.”

Details related to the poster presentation are as follows:
Title: Clinical and genomic correlation of a CLIA certified organoid based functional test in breast cancer patients
Lead Author: Astrid Margossian, MD, PhD
Senior Author: Carla Grandori, MD, PhD
Poster Session: Poster Session 4: Response Prediction Biomarkers I (PS04/01)
Poster Session Date: December 9, 2020 at 8:00 am CT

About the PARIS® Test 
The PARIS® Test is based on the capability to propagate patient-specific cancer cells as organoids outside the body and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where a treatment path is not clear, such as many metastatic and recurrent cancers, the PARIS® Test provides crucial information to treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine

SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:

Stephanie Carrington
[email protected]
646-277-1282

 

CALGARY, Alberta, Dec. 09, 2020 (GLOBE NEWSWIRE) — News Release – TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) today announced that its Board of Directors (Board) declared quarterly dividends on outstanding Series 11, 13 and 15 Cumulative First Preferred Shares as follows:

• For the period up to but excluding February 26, 2021, payable on February 26, 2021 to shareholders of record at the close of business on February 1, 2021:
  • Series 11 (TRP.PR.G) – $0.2094375 per share
  • Series 13 (TRP.PR.J) – $0.34375 per share
  • Series 15 (TRP.PR.K) – $0.30625 per share

These dividends are designated by TC Energy to be eligible dividends for purposes of the Income Tax Act (Canada) and any similar provincial or territorial legislation. An enhanced dividend tax credit applies to eligible dividends paid to Canadian residents.

Common shares purchased with reinvested cash dividends under TC Energy’s Dividend Reinvestment and Share Purchase Plan (DRP) will be acquired on the Toronto Stock Exchange at 100 per cent of the weighted average purchase price. The DRP is available for dividends payable on TC Energy’s common and preferred shares.

About TC Energy

We are a vital part of everyday life — delivering the energy millions of people rely on to power their lives in a sustainable way. Thanks to a safe, reliable network of natural gas and crude oil pipelines, along with power generation and storage facilities, wherever life happens — we’re there. Guided by our core values of safety, responsibility, collaboration and integrity, our more than 7,500 people make a positive difference in the communities where we operate across Canada, the U.S. and Mexico.

TC Energy’s common shares trade on the Toronto (TSX) and New York (NYSE) stock exchanges under the symbol TRP. To learn more, visit us at TCEnergy.com.

FORWARD-LOOKING INFORMATION

This release contains certain information that is forward-looking and is subject to important risks and uncertainties (such statements are usually accompanied by words such as “anticipate”, “expect”, “believe”, “may”, “will”, “should”, “estimate”, “intend” or other similar words). Forward-looking statements in this document are intended to provide TC Energy security holders and potential investors with information regarding TC Energy and its subsidiaries, including management’s assessment of TC Energy’s and its subsidiaries’ future plans and financial outlook. All forward-looking statements reflect TC Energy’s beliefs and assumptions based on information available at the time the statements were made and as such are not guarantees of future performance. As actual results could vary significantly from the forward-looking information, you should not put undue reliance on forward-looking information and should not use future-oriented information or financial outlooks for anything other than their intended purpose. We do not update our forward-looking information due to new information or future events, unless we are required to by law. For additional information on the assumptions made, and the risks and uncertainties which could cause actual results to differ from the anticipated results, refer to the most recent Quarterly Report to Shareholders and Annual Report filed under TC Energy’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission at www.sec.gov .

-30-

Media Enquiries:

Jaimie Harding / Hejdi Carlsen
403.920.7859 or 800.608.7859

Investor & Analyst Enquiries:

David Moneta / Hunter Mau
403.920.7911 or 800.361.6522

PDF available: http://ml.globenewswire.com/Resource/Download/7e4437ef-8cb2-4778-8655-43b2ca440429

League City, Texas, Dec. 09, 2020 (GLOBE NEWSWIRE) — Muscle Maker, Inc. (Nasdaq: GRIL) the parent company of Muscle Maker Grill, Healthy Joe’s, Meal Plan AF & MMG Burger Bar, a fast-casual brand known for serving “healthier for you” meals, today announced it has officially opened its first partnership location with REEF Neighborhood Kitchens in NYC. The delivery-only kitchen will be located in Long Island City, New York City’s up-and-coming neighborhood just over the Queensboro bridge from Manhattan.

In August the company announced the REEF partnership with plans to open the first location in Union City, NJ. Union City will be our second location and will open early 2021. Our first REEF Neighborhood Kitchen will open in Long Island City and will operate on a delivery-only model, where customers can enjoy Muscle Maker Grill dishes packed with fresh veggies, all-natural chicken breast or grass-fed steak by placing their order through any one of the established third-party delivery platforms like DoorDash, GrubHub or UberEats, and have it brought right to their door via contactless delivery. The Long Island City neighborhood has seen explosive residential growth over the last few years, that combined with the continued trend of more and more people working from home, makes for a perfect location for the company’s first REEF location.

In response to the ongoing pandemic, restaurants have transformed the way they do business. MMG recognized this trend early on and has announced various types of ghost kitchen projects and shipped direct-to-consumers meal plan programs throughout the U.S. REEF’s proximity-based network to consumers across the country gives fast-casual restaurants the ability to build and scale very quickly. REEF recently completed a $700m capital raise with Mubadala and SoftBank, along with the company’s network of 4,500 parking locations makes for a strong partnership with MMG and brands.

“REEF’s Neighborhood Kitchens make perfect sense for Muscle Maker Grill as a part of its non-traditional location growth strategy,” said Michael Roper, Chief Executive Officer of Muscle Maker Grill. “Consumers and restaurant owners are increasingly embracing technological evolution and these delivery-only models continue to play an important role in the restaurant industry; as indicated by the exponential growth delivery has represented in the Quick Service Restaurant segment over the last year. This is a trend that we expect to continue, not only due to the current business climate and desire to social distance, but also as consumers grow comfortable with the breadth, quality and speed at which offerings are made available. Through REEF we believe we can scale quickly in major metropolitan markets with limited capital expenditure, which we expect to allow us to expand our nationwide brand awareness and serve up our delicious “healthier for you” options to guests.”

“We’re excited to officially bring Muscle Maker Grill’s fast-casual menu to New Yorkers,” said Carl Segal, Chief Operating Officer at REEF. “REEF’s ecosystem is intended to boost the reach of our restaurant partners with our network of neighborhood kitchens. In turn, this helps power their growth in important target markets.”

About Muscle Maker Grill

Founded in 1995 in Colonia, New Jersey, Muscle Maker Grill features high quality, great tasting food, freshly prepared with proprietary recipes. The menu, created with the guest’s health in mind, is lean and protein based. It features all-natural chicken, grass-fed steak, lean turkey, whole wheat pasta, wraps, bowls and more. It also offers a wide selection of fruit smoothies in a variety of assorted flavors, protein shakes and supplements. For more information on Muscle Maker Grill, visit www.musclemakergrill.com.

About REEF

REEF’s mission is to connect the world to your block. We transform underutilized urban spaces into neighborhood hubs that connect people to locally curated goods, services, and experiences. With an ecosystem of 4,500 locations and a team of 15,000 people, REEF is the largest operator of mobility, logistics hubs, and neighborhood kitchens in the United States. Together we are leveraging the power of proximity to keep our communities moving forward in a sustainable and thoughtful way. 

Forward-Looking Statements

This press release may include “forward-looking statements” pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. To the extent that the information presented in this press release discusses financial projections, information, or expectations about our business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as “should”, “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in documents that we file from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Muscle Maker, Inc does not undertake any duty to update any forward-looking statements except as may be required by law.

Contact:

Muscle Maker Grill Marketing
[email protected]

Investor Relations:
[email protected]

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on DANYELZA® (naxitamab-gqgk) for the treatment of Refractory/Relapsed High-Risk Neuroblastoma was given at the ESMO Immuno-Oncology Virtual Congress 2020, which is being held December 9 through December 12, 2020. The DANYELZA data was presented by Dr. Jaume Mora from SJD Barcelona Children’s Hospital, Spain and Dr. Daniel A. Morgenstern from The Hospital for Sick Children, Toronto, Canada.

In the Company’s Study 201, a total of 95% of the infusions were administered in an outpatient setting. The median infusion time was 37 minutes, and all infusions were completed in less than 2 hours. The adherence rate was deemed very satisfactory, as 98% of the infusions were completed as planned, and the treatments appeared to be generally well tolerated. By independent review, the overall response rate (“ORR”) in Study 201 was 68% with 59% complete responses (“CR”). In refractory patients, the ORR was 71% with 64% CR, and in relapsed patients the ORR was 63% with 50% CR.

DANYELZA 40mg/10ml was recently approved by the U.S. FDA. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. During the Company’s Study 201, DANYELZA was primarily administered to patients in an outpatient setting three times in a week and the treatment was repeated every four weeks.

“I am very pleased to see that 98% of the infusions were completed as planned and 95% of the infusions were outpatient. Furthermore, the response rates achieved in these patients, who were either refractory to frontline treatment or had relapsed are notable, as this is a difficult to treat patient population, and the responses are based on antibody treatment alone, and not combination treatment with chemotherapy,” said Thomas Gad, founder, Chairman and President.

“We are pleased that Study 201 showed that when DANYELZA is given in an outpatient setting with a high degree of treatment adherence, it addressed a significant unmet medical need in an efficient way. In addition, in Study 201 we saw that the median infusion time was just over half an hour, and when compared to the duration of the first infusion, the subsequent infusion times were generally lower, which we believe is great news for children living with refractory/relapsed high-risk neuroblastoma,” said Dr. Claus Moller, Chief Executive Officer.

Researchers at Memorial Sloan Kettering Cancer Center (“MSK”) developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests related to the compound and Y-mAbs.

About DANYELZA® (naxitamab-gqgk)

DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest, anaphylaxis, hypotension, bronchospasm and stridor and neurotoxicity, such as severe neuropathic pain, transverse myelitis and reversible posterior leukoencephalopathy syndrome. See full Prescribing Information for complete Boxed Warning and other important safety information.

About
Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development and commercialization plans; the benefits, safety and efficacy of DANYELZA, current and future clinical and pre-clinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in our Annual Report on Form 10-K and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

“DANYELZA” and “Y-mAbs” are registered trademarks of Y-mAbs Therapeutics, Inc.        

Contact:

Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
USA

+1 646 885 8505

E-mail: [email protected]

Sacramento, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Northern California-based Sutter Health today announced the creation of its Institute for Advancing Health Equity, marking another major step in the not-for-profit system’s work to help eliminate health disparities within its integrated network and across the United States. Health inequities among specific population groups and geographic areas have long been identified as one of the major deficiencies of the U.S. health care system, and, as a national leader in health care quality, Sutter Health is dedicated to continuing to drive actions, like today’s Institute launch, to foster more equitable health outcomes for all.

Building on more than a decade of experience in health equity research and patient-centered solutions, the Institute will serve as an innovation incubator that generates knowledge and shares its expertise to eliminate health disparities. Leveraging the resources and reach provided by Sutter’s coordinated network, the new Institute will:

• Facilitate pragmatic research that can be directly applied in clinical settings using Sutter’s existing health equity metrics and proven data analytics.
• Promote clinical and community-based initiatives and develop trainings to tackle and prevent disparities among patient populations.
• Convene experts, advocates and patients to explore health inequities and generate evidence-based solutions.

“At Sutter Health, we have been working for years to advance health equity and eliminate gaps in health outcomes for vulnerable patient groups. For example, we are incredibly proud that our C-section and maternal mortality rates now sit well below California’s nationally leading average and our maternal mortality rate demonstrates no inequity in race or ethnicity. The establishment of the Institute is a crucial next step in our commitment to providing more equitable outcomes and overcoming injustices in the nation’s health care system,” said Sarah Krevans, president and CEO, Sutter Health.

A Proven Track Record of Advancing Health Equity

Since its establishment, Sutter’s Advancing Health Equity team has focused on developing insights and solutions to improve health outcomes for all patients. Over the past several years, our experienced team of clinicians, researchers and administrators have examined data in a number of areas to address inequities — including maternal health, chronic disease management, opioid prescribing behavior, cancer screening and, most recently, COVID-19. Highlights include:

• Health Equity Index (HEI): This groundbreaking metric developed by Sutter uses analytics and dynamic population data to measure health disparities across patient groups and develop interventions to enhance equity. Sutter applied the HEI within its own network and shared the tool with other health systems so they can generate comparable insights.

• Maternal Care Collaboration: Through our work with a statewide public-private partnership on maternal health, and by employing best practices over the last several years, Sutter Health’s C-section and maternal mortality rates currently sit well below California’s nationally leading average. Our maternal mortality and c-section rates also demonstrates equitable care across racial and ethnic groups.

• Asthma in Oakland’s African American Community: Using the HEI, Sutter identified higher-than- expected rates of emergency visits for asthma among African American patients in Oakland. The insights led directly to a new collaboration on a community-based program for Black patients in East Oakland and Berkeley to support asthma management.

• COVID-19 Disparities: An analysis of Sutter’s COVID-19 patients revealed Black patients are nearly three times more likely to be hospitalized than their non-Hispanic, white counterparts and they arrive on average later and sicker to Sutter facilities. This research is yielding a better understanding of the national conversation around COVID-19’s disproportionate impact on communities of color and has fueled the Health Equity team’s efforts to partner with community-based programs that aim to expand testing and contact tracing for the most vulnerable.  

A Microcosm for the Nation
— Sutter is Well Positioned to Tackle Disparities 

As an integrated health care delivery network serving more than 3 million patients across 22 Northern California counties, Sutter Health serves one of the most geographically and demographically diverse patient populations in the country. That diversity extends across Sutter’s clinical settings and data environments, providing the team with unmatched access to the resources and reach necessary to generate robust findings around health disparities and test new models for advancing health equity that can be applied nationally.

“By creating the Institute, Sutter continues to lean into the incredible insights and benefits provided by our integrated network to drive solutions on key issues like health equity,” said Dr. Stephen Lockhart, chief medical officer, Sutter Health. “Transforming health care to make it more equitable will impact countless lives, meeting our mission of providing compassionate, high-quality care that affords the same high-quality outcomes to everyone, regardless of their circumstances. I am so proud to be furthering our commitment to eliminate health disparities through today’s actions.”  

About the Institute for Advancing Health Equity

Embedded within the Sutter Health system, the Institute for Advancing Health Equity will leverage the network’s resources, data and partnerships to not only examine where health inequities exist but find ways to better address them.

“We have an opportunity and obligation to move beyond bringing these issues to light. We must begin to develop proactive solutions to address and prevent health inequity and disparities that can be translated into our care settings and communities,” said Kristen Azar R.N., MSN/MPH, the new institute’s scientific medical director, Sutter Health.

With the equivalent of approximately six dedicated full-time employees to start, and growing to 11 over the next few years, the team will increase awareness of health disparities, influence policy and design interventions that can be applied within their network and beyond.

“Our Institute’s unique data-driven, evidence-based model fills a much-needed gap in the work to better understand and address health disparities,” said Leon Clark, chief research and health equity officer, Sutter Health. “By launching a formal hub, Sutter and those we collaborate with can accelerate our ability to share knowledge, establish proven best practices and create a more equitable health care system for generations to come.”

About Sutter Health

Sutter Health is more than 60,000 people strong thanks to its integrated network of clinicians, employees and volunteers. Headquartered in Sacramento, California, Sutter Health provides access to high-quality, affordable care for more than 3 million Northern Californians through its network of hospitals, medical foundations, urgent and walk-in care centers, home health and hospice services, and network of more than 5,500 independent doctors. Recognized as a national leader in quality, Sutter’s integrated health care system provides access to patient-centered, coordinated care that outperforms state and national averages in nearly every quality measure. Grounded in its not-for-profit mission, Sutter Health invests hundreds of millions annually in its communities and to support community clinics and community-based hospitals—providing care for the most vulnerable populations and strengthening the fabric of our communities.

For more information about the Sutter Health network visit:

sutterhealth.org | vitals.sutterhealth.org | facebook.com/sutterhealth | twitter.com/sutterhealth.

 

#          #          #

Angie Sheets
Sutter Health
1-800-428-7377
[email protected]